(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 27 April 2006 (27.04.2006)

(10) International Publication Number WO 2006/045037 A3

(51)	International	Patent	Classification:
------	---------------	--------	-----------------

 A61K 49/00 (2006.01)
 A61K 38/00 (2006.01)

 A01N 61/00 (2006.01)
 G01N 33/00 (2006.01)

 A01N 37/18 (2006.01)
 A01K 67/00 (2006.01)

 A61K 31/00 (2006.01)
 A01K 67/033 (2006.01)

(21) International Application Number:

PCT/US2005/037875

- (22) International Filing Date: 19 October 2005 (19.10.2005)
- (25) Filing Language: Eng
- (26) Publication Language: English

(30) Priority Data:

10/969,335 19 October 2004 (19.10.2004) US 11/194,115 29 July 2005 (29.07.2005) US

- (71) Applicant (for all designated States except US): ELAN PHARMACEUTICALS, INC. [US/US]; 800 Gateway Boulevard, South San Francisco, California 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHILCOTE, Tamle, J. [US/US]; 187 Magellan Avenue, San Francisco, California 94116 (US). GOLDSTEIN, Jason [US/US]; 1420 El Camino Real #1, Burlingame, California 94010 (US). ANDERSON, John, P. [US/US]; 1323-A Lyon Street, San Francisco, California 94115 (US). WALKER, Donald [US/US]; 33 Mozden Lane, Pleasant Hill, CA 94523 (US).
- (74) Agents: LIEBESCHUETZ, Joe et al.; TOWNSEND AND TOWNSEND AND CREW LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 21 September 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRUNCATED FRAGMENTS OF ALPHA-SYNUCLEIN IN LEWY BODY DISEASE

(57) Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/37875

A. CLASSIFICATION OF SUBJECT MATTER IPC: A61K 49/00(2006.01);A01N 61/00(2006.01),37/18(2006.01);A61K 31/00(2006.01),38/00(2006.01);G01N 33/00(2006.01);A01K 67/00(2006.01),67/033(2006.01)							
Heno:	424/0 1.514/1 2.900/2 0 12						
USPC: According to	424/9.1;514/1,2;800/3,9,12 International Patent Classification (IPC) or to both nat	tional classification and IPC					
B. FIELI	DS SEARCHED						
Minimum do	cumentation searched (classification system followed b	y classification symbols)					
U.S. : 42	4/9.1; 514/1,2; 800/3,9,12		·····				
Documentation	on searched other than minimum documentation to the	extent that such documents are included in	the fields searched				
	ta base consulted during the international search (name ontinuation Sheet	e of data base and, where practicable, search	a terms used)				
C. DOC	JMENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document, with indication, where a		Relevant to claim No.				
Х	TSIM, K.W. et al., Monoclonal antibodies specific for acetylcholinesterase from chick muscle. J. Neuroche 104, see abstract		52				
х	HAMBURGER, A.W., et al., Isolation and characterization of monoclonal antibodies reactive with endothelial cells. Tissue Cell. 1985, Vol. 17. No. 4, pages 451-459, abstract		52				
х	US 6,780,971 B2 (Wolozin et al) 24 August 2004 (24	4.08.2004), column 17, lines 53-62	1, 4				
A	TAKAHASHI, M. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neuroscience Letters. 2003, Vol. 336, pages 155-158.		1-52				
Further	documents are listed in the continuation of Box C.	See patent family annex.					
• S	pecial categories of cited documents:	"T" later document published after the intern date and not in conflict with the applicat					
"A" document particular	defining the general state of the art which is not considered to be of relevance	principle or theory underlying the invent	ion				
"E" earlier app	dication or patent published on or after the international filing date	"X" document of particular relevance; the cla considered novel or cannot be considere when the document is taken alone					
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the cla considered to involve an inventive step with one or more other such documents,	when the document is combined				
"O" document	referring to an oral disclosure, use, exhibition or other means	obvious to a person skilled in the art					
	published prior to the international filing date but later than the te claimed	"&" document member of the same patent family					
Date of the actual completion of the international search		Date of mailing of the international search	report				
07 June 2006 (07.06.2006)		20 JUI 2006	<u></u>				
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450		Ram Shukla, Ph.D. Telephone No. (571) 272-1600	Harrigh				
	uandria, Virginia 22313-1450 (571) 273-3201	100phone 140. (371) 272-1000	·				

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No. PCT/US05/37875

ategory •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim l
A	OKOCHI, M. Constitutive Phosphorylation of the Parkinson's Disease Associated alpha- Synuclein. The Journal of Biological Chemistry. January 2000, Vol 275. No. 1, pages 390- 397.	1-52
A	KIM, T.D. et al. Structural Changes in alpha-Synuclein Affect its Chaperone-like Activity In Vitro. Protein Science. 2000, Vol 9. pages 2489-2496	1-52
A	HOYER, W. et al., Dependence of alpha-Synuclein Aggregate Morphology on Solution Conditions. J. Mol. Biol. 2002, Vol 322, pages 383-393.	1-52
!		
į		
	·	

1		
•	1	

International application No. INTERNATIONAL SEARCH REPORT PCT/US05/37875 Continuation of B. FIELDS SEARCHED Item 3: Google, EAST, STN search terms: alpha-synuclein, phosporylated, 1-115, 1-133, 1-135, 12C6, 7G8